Touchstone International Medical Science Co., Ltd. (SHA:688013)
China · Delayed Price · Currency is CNY 22.75
+0.43 (1.93%)
Sep 14, 2026, 3:00 PM CST
SHA:688013 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 283.9 | 326.73 | 272.34 | 253.6 | 231.73 | 213.74 |
Other Revenue | 0 | 0 | 0.03 | 0.04 | 0.31 | 0 |
| 283.9 | 326.73 | 272.37 | 253.65 | 232.03 | 213.74 | |
Revenue Growth | -4.02% | 19.96% | 7.38% | 9.31% | 8.56% | 30.85% |
Cost of Revenue | 103.66 | 118.53 | 113.64 | 111.8 | 99.8 | 91.27 |
Gross Profit | 180.25 | 208.2 | 158.73 | 141.85 | 132.23 | 122.47 |
Selling, General & Admin | 78.1 | 81.3 | 74.66 | 71.9 | 61.66 | 62.37 |
Research & Development | 57.41 | 51.3 | 35.99 | 35.32 | 34.75 | 29.28 |
Other Operating Expenses | 2.15 | 1.86 | 1.79 | 4.75 | 2.39 | 2.13 |
Operating Expenses | 139.23 | 136.03 | 112.38 | 112.27 | 98.97 | 94.05 |
Operating Income | 41.02 | 72.18 | 46.34 | 29.58 | 33.27 | 28.41 |
Interest Expense | -0.47 | -0.47 | -0.23 | -0.09 | -0.16 | - |
Interest & Investment Income | 0.89 | 2.87 | 9.12 | 8.03 | 4.76 | 11.15 |
Currency Exchange Gain (Loss) | 10.66 | 10.66 | -0.01 | 2.47 | 3.94 | 4 |
Other Non Operating Income (Expenses) | -13.27 | -0.2 | -0.17 | 1.89 | -0.12 | -0.06 |
EBT Excluding Unusual Items | 38.82 | 85.03 | 55.06 | 41.88 | 41.69 | 43.51 |
Gain (Loss) on Sale of Investments | 16.1 | 8.48 | -1.89 | 4.06 | 2.09 | 0.44 |
Gain (Loss) on Sale of Assets | 0.45 | 0.4 | -0 | 0 | 0.02 | 0.52 |
Asset Writedown | 0.14 | - | - | - | - | - |
Legal Settlements | - | - | - | - | - | -1.08 |
Other Unusual Items | 1.26 | 1.26 | 1.66 | 2.01 | 2.28 | 2.71 |
Pretax Income | 56.78 | 95.17 | 54.83 | 47.95 | 46.08 | 46.09 |
Income Tax Expense | 6.06 | 9.98 | 2.94 | 0.64 | 2.89 | 4.67 |
Net Income | 50.71 | 85.19 | 51.89 | 47.31 | 43.2 | 41.42 |
Net Income to Common | 50.71 | 85.19 | 51.89 | 47.31 | 43.2 | 41.42 |
Net Income Growth | -28.83% | 64.15% | 9.69% | 9.53% | 4.29% | 18.52% |
Shares Outstanding (Basic) | 81 | 80 | 80 | 79 | 80 | 80 |
Shares Outstanding (Diluted) | 81 | 81 | 81 | 82 | 82 | 81 |
Shares Change | -1.45% | 0.05% | -0.60% | 0.09% | 0.35% | 25.49% |
EPS (Basic) | 0.63 | 1.06 | 0.65 | 0.60 | 0.54 | 0.52 |
EPS (Diluted) | 0.63 | 1.05 | 0.64 | 0.58 | 0.53 | 0.51 |
EPS Growth | -27.78% | 64.06% | 10.35% | 9.43% | 3.92% | -5.56% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -31.95 | -18.76 | 11.47 | 64.54 | 2.73 | 51.77 |
Free Cash Flow Per Share | -0.40 | -0.23 | 0.14 | 0.79 | 0.03 | 0.64 |
Dividend Per Share | 1.300 | 1.300 | 1.000 | - | 0.250 | 0.200 |
Dividend Growth | 160.00% | 30.00% | - | - | 25.00% | 0% |
Gross Margin | 63.49% | 63.72% | 58.28% | 55.92% | 56.99% | 57.30% |
Operating Margin | 14.45% | 22.09% | 17.02% | 11.66% | 14.34% | 13.29% |
Profit Margin | 17.86% | 26.07% | 19.05% | 18.65% | 18.62% | 19.38% |
Free Cash Flow Margin | -11.25% | -5.74% | 4.21% | 25.44% | 1.18% | 24.22% |
EBITDA | 53.07 | 83.53 | 55.99 | 38.63 | 41.35 | 35.64 |
EBITDA Margin | 18.69% | 25.56% | 20.56% | 15.23% | 17.82% | 16.67% |
D&A For EBITDA | 12.05 | 11.35 | 9.64 | 9.05 | 8.09 | 7.22 |
EBIT | 41.02 | 72.18 | 46.34 | 29.58 | 33.27 | 28.41 |
EBIT Margin | 14.45% | 22.09% | 17.02% | 11.66% | 14.34% | 13.29% |
Effective Tax Rate | 10.67% | 10.49% | 5.36% | 1.33% | 6.27% | 10.14% |
Revenue as Reported | 326.73 | 326.73 | 272.37 | 253.65 | 232.03 | 213.74 |